Value through Innovation31 October 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

28.06.2012

New publication in The Lancet: Two-year study in over 1,500 patients compares Trajenta® (linagliptin) to the commonly prescribed sulphonylurea glimepiride

- EX US & UK Medical Media Only
25.06.2012

No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa® (dabigatran etexilate) compared to enoxaparin for VTE prevention after orthopaedic surgery

20.06.2012

First study to evaluate alternative to warfarin for mechanical heart valve patients launched with Pradaxa® (dabigatran etexilate)

- For Non-US, Non-UK & Non-Canadian Media Only
18.06.2012

AF patients who require surgery benefit from a shorter treatment interruption on dabigatran etexilate (Pradaxa®) compared to warfarin

- For Non-US, Non-UK & Non-Canadian Media Only
18.06.2012

Boehringer Ingelheim BioXcellence:
Distinctive brand for the biopharmaceutical contract manufacturing business

12.06.2012

Boehringer Ingelheim once again certified as a family-friendly company

11.06.2012

Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine

- EX UK. Medical Media Only.
09.06.2012

New analysis presented at ADA shows improvement in albuminuria with linagliptin in patients at high risk of declining renal function

- EX US & UK. Medical Media Only.
09.06.2012

New data demonstrate sustained glucose reduction and weight loss up to 90 weeks with investigational SGLT-2 inhibitor, empagliflozin*

- EX US & UK. Medical Media Only.
09.06.2012

New linagliptin phase III data demonstrate significant reductions in blood glucose with no additional risk of hypoglycaemia when combined with insulin in patients with type 2 diabetes

- EX US & UK. Medical Media Only.
06.06.2012

FDA affirms superiority of Pradaxa® (dabigatran etexilate) 150mg over warfarin in reduction of both ischaemic and haemorrhagic strokes

- For Non-US, Non-UK & Non-Canadian Media Only
05.06.2012

Boehringer Ingelheim and Lilly to feature 30 presentations on type 1 and type 2 diabetes at the 72nd American Diabetes Association Scientific Sessions

- EX US & UK. Medical Media Only.
04.06.2012

Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial

- For NON-US media only
01.06.2012

Boehringer Ingelheim launches first-of-a-kind fundraising model to support disease awareness projects

- For NON-US Media Only
31.05.2012

Boehringer Ingelheim expands development capacities with new technical centre

30.05.2012

Boehringer Ingelheim further strengthens animal health presence in China: Manufacturing joint venture for veterinary vaccines

25.05.2012

Jentadueto™ (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with Type 2 Diabetes in Europe

- For Non-U.S. and Non-UK Media
23.05.2012

€100,000 in reward donations for projects fundraising to prevent atrial fibrillation-related strokes

- For NON-US Media Only